|
|
Article: Lexapro is the Leading Single Agent In First- and Second-Line Patient Share for the Treatment of Generalized Anxiety Disorder.
- Article from:
- PR Newswire
- Article date:
- June 18, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Presence of Comorbid Depression Influences Physicians to Prescribe a Selective Serotonin Reuptake Inhibitor, According to a New Report from Decision Resources
WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Lexapro is the leading single agent used in anxiety therapy with 11.7 percent and 14.9 percent of first- and second-line patient share, respectively. According to surveyed psychiatrists and primary care physicians (PCPs), Lexapro is distinguished by its superior safety and tolerability profile; physicians specifically mention ...